BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Alzheimer's Disease readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Alzheimer's Disease\,
  from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06585787-712@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261124
DTEND;VALUE=DATE:20261125
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 585787)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Study to Evaluate KarXT as a Treatment for Psychosis As
 sociated With Alzheimer's Disease (ADEPT-4)\nEstimated primary completion:
  24 November 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/xa
 nomeline-trospium-chloride#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06585787
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07107074-754@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:AD04: Phase 2 readout est. (NCT07107074)
DESCRIPTION:AD04\, phase 2\, Alzheimer's Disease.\nStudy: Effects of a Wide
 ly Used Vaccine Adjuvant in Subjects With Early Alzheimer's Disease Double
 -blind Study to Assess the Safety and Efficacy of AD04 in Patients With Ea
 rly Alzheimer's Disease - ADVANCE\nEstimated primary completion: December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/ad04#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07107074
URL:https://assetmemo.bio/drug/ad04#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05397639-701@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Masupirdine: Phase 3 readout est. (NCT05397639)
DESCRIPTION:Masupirdine\, phase 3\, Alzheimer's Disease.\nStudy: Masupirdin
 e for the Treatment of Agitation in Dementia of the Alzheimer's Type\nEsti
 mated primary completion: December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/masupirdine#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05397639
URL:https://assetmemo.bio/drug/masupirdine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06602258-665@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261203
DTEND;VALUE=DATE:20261204
SUMMARY:Leqembi (Lecanemab): Phase 2 readout est. (NCT06602258)
DESCRIPTION:Leqembi (Lecanemab)\, phase 2\, Alzheimer's Disease.\nStudy: A 
 Study of E2814 With Concurrent Lecanemab Treatment in Participants With Ea
 rly Alzheimer's Disease\nEstimated primary completion: 3 December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/lecanemab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06602258
URL:https://assetmemo.bio/drug/lecanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06602258-686@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261203
DTEND;VALUE=DATE:20261204
SUMMARY:Etalanetug: Phase 2 readout est. (NCT06602258)
DESCRIPTION:Etalanetug\, phase 2\, Alzheimer's Disease.\nStudy: A Study of 
 E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzhe
 imer's Disease\nEstimated primary completion: 3 December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/etalanetug#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06602258
URL:https://assetmemo.bio/drug/etalanetug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06126224-712@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261209
DTEND;VALUE=DATE:20261210
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 126224)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Study to Assess Efficacy and Safety of KarXT for the Tr
 eatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)\nEstima
 ted primary completion: 9 December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06126224
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06268886-688@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:Moponetug: Phase 2 readout est. (NCT06268886)
DESCRIPTION:Moponetug\, phase 2\, Alzheimer's Disease.\nStudy: Study to Eva
 luate the Efficacy\, Safety\, and Tolerability of an Anti-MTBR Tau Monoclo
 nal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease\n
 Estimated primary completion: 17 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/moponetug#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06268886
URL:https://assetmemo.bio/drug/moponetug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06544616-685@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:ACI-35.030: Phase 2 readout est. (NCT06544616)
DESCRIPTION:ACI-35.030\, phase 2\, Alzheimer's Disease.\nStudy: A Study of 
 JNJ-64042056 in Participants With Preclinical Alzheimer's Disease\nEstimat
 ed primary completion: 22 December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/aci-35-030#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06544616
URL:https://assetmemo.bio/drug/aci-35-030#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06803823-772@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:ONO-2020: Phase 2 readout est. (NCT06803823)
DESCRIPTION:ONO-2020\, phase 2\, Alzheimer's Disease.\nStudy: A Study of ON
 O-2020 in Patients With Agitation Associated With Alzheimer's Disease Deme
 ntia\nEstimated primary completion: 31 December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ono-2020#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06803823
URL:https://assetmemo.bio/drug/ono-2020#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03887455-665@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Leqembi (Lecanemab): Phase 3 readout est. (NCT03887455)
DESCRIPTION:Leqembi (Lecanemab)\, phase 3\, Alzheimer's Disease.\nStudy: A 
 Study to Confirm Safety and Efficacy of Lecanemab in Participants With Ear
 ly Alzheimer's Disease\nEstimated primary completion: 31 December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/lecanemab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT03887455
URL:https://assetmemo.bio/drug/lecanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05531656-719@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Zervimesine: Phase 2 readout est. (NCT05531656)
DESCRIPTION:Zervimesine\, phase 2\, Alzheimer's Disease.\nStudy: A Study to
  Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease\n
 Estimated primary completion: 31 May 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/zervimesine#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05531656
URL:https://assetmemo.bio/drug/zervimesine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221344-694@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:ARO-MAPT-SC: Phase 1/2 readout est. (NCT07221344)
DESCRIPTION:ARO-MAPT-SC\, phase 1/2\, Alzheimer's Disease.\nStudy: Trial of
  ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer
 's Disease or Primary Tauopathies\nEstimated primary completion: June 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/aro-mapt-sc#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07221344
URL:https://assetmemo.bio/drug/aro-mapt-sc#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07027072-730@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tisolagiline: Phase 2 readout est. (NCT07027072)
DESCRIPTION:Tisolagiline\, phase 2\, Alzheimer's Disease.\nStudy: Study to 
 Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's D
 isease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's
  Disease\nEstimated primary completion: 30 June 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/tisolagiline#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07027072
URL:https://assetmemo.bio/drug/tisolagiline#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04639050-670@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Trontinemab: Phase 1/2 readout est. (NCT04639050)
DESCRIPTION:Trontinemab\, phase 1/2\, Alzheimer's Disease.\nStudy: Brainshu
 ttle AD: A Multiple Ascending Dose Study to Investigate the Safety\, Toler
 ability\, Pharmacokinetics\, and Pharmacodynamics of RO7126209 Following I
 ntravenous Infusion in Participants With Prodromal or Mild to Moderate Alz
 heimer's Disease\nEstimated primary completion: 31 July 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/trontinemab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04639050
URL:https://assetmemo.bio/drug/trontinemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05980949-712@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270907
DTEND;VALUE=DATE:20270908
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT05
 980949)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: Open-Label Extension Study to Assess the Long-Term Safety
  and Tolerability of KarXT in Subjects With Psychosis Associated With Alzh
 eimer's Disease (ADEPT-3)\nEstimated primary completion: 7 September 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/xanomeline-trospium-
 chloride#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05980949
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07553338-1012@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Leronlimab: Phase 2 readout est. (NCT07553338)
DESCRIPTION:Leronlimab\, phase 2\, Alzheimer's Disease.\nStudy: Safety Asse
 ssment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's D
 isease\nEstimated primary completion: November 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/leronlimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07553338
URL:https://assetmemo.bio/drug/leronlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05026866-664@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Kisunla (Donanemab): Phase 3 readout est. (NCT05026866)
DESCRIPTION:Kisunla (Donanemab)\, phase 3\, Alzheimer's Disease.\nStudy: A 
 Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's D
 isease (TRAILBLAZER-ALZ 3)\nEstimated primary completion: November 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/donanemab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05026866
URL:https://assetmemo.bio/drug/donanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06887192-707@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Betovumeline/fesoterodine (ML-007C-MA): Phase 2 readout est. (NCT06
 887192)
DESCRIPTION:Betovumeline/fesoterodine (ML-007C-MA)\, phase 2\, Alzheimer's 
 Disease.\nStudy: A Study to Assess the Efficacy and Safety of ML-007C-MA f
 or the Treatment of Alzheimer's Disease Psychosis\nEstimated primary compl
 etion: December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /betovumeline-fesoterodine-ml-007c-ma#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06887192
URL:https://assetmemo.bio/drug/betovumeline-fesoterodine-ml-007c-ma#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06709014-738@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Buntanetap: Phase 3 readout est. (NCT06709014)
DESCRIPTION:Buntanetap\, phase 3\, Alzheimer's Disease.\nStudy: A Double-bl
 ind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants
  With Early AD\nEstimated primary completion: December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/buntanetap#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06709014
URL:https://assetmemo.bio/drug/buntanetap#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06651567-708@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271228
DTEND;VALUE=DATE:20271229
SUMMARY:Deulumateperone: Phase 2 readout est. (NCT06651567)
DESCRIPTION:Deulumateperone\, phase 2\, Alzheimer's Disease Agitation.\nStu
 dy: A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment
  of Agitation Associated With Alzheimer's Dementia\nEstimated primary comp
 letion: 28 December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/deulumateperone#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06651567
URL:https://assetmemo.bio/drug/deulumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06159673-702@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Remlifanserin: Phase 2/3 readout est. (NCT06159673)
DESCRIPTION:Remlifanserin\, phase 2/3\, Alzheimer's Disease.\nStudy: ACP-20
 4 in Adults With Alzheimer's Disease Psychosis\nEstimated primary completi
 on: January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rem
 lifanserin#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06159673
URL:https://assetmemo.bio/drug/remlifanserin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05303701-729@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Tertomotide: Phase 3 readout est. (NCT05303701)
DESCRIPTION:Tertomotide\, phase 3\, Alzheimer's Disease.\nStudy: GV1001 Sub
 cutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)\
 nEstimated primary completion: January 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/tertomotide#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05303701
URL:https://assetmemo.bio/drug/tertomotide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07399171-731@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:HT-4253: Phase 2 readout est. (NCT07399171)
DESCRIPTION:HT-4253\, phase 2\, Alzheimer's Disease.\nStudy: Study to Evalu
 ate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APO
 E4 Carriers\nEstimated primary completion: February 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/ht-4253#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07399171
URL:https://assetmemo.bio/drug/ht-4253#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07169578-670@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280216
DTEND;VALUE=DATE:20280217
SUMMARY:Trontinemab: Phase 3 readout est. (NCT07169578)
DESCRIPTION:Trontinemab\, phase 3\, Alzheimer's Disease.\nStudy: A Study of
  Trontinemab in Participants With Early Symptomatic Alzheimer's Disease\nE
 stimated primary completion: 16 February 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/trontinemab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07169578
URL:https://assetmemo.bio/drug/trontinemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07170150-670@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280216
DTEND;VALUE=DATE:20280217
SUMMARY:Trontinemab: Phase 3 readout est. (NCT07170150)
DESCRIPTION:Trontinemab\, phase 3\, Alzheimer's Disease.\nStudy: A Clinical
  Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's D
 isease\nEstimated primary completion: 16 February 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/trontinemab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07170150
URL:https://assetmemo.bio/drug/trontinemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06947941-712@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280221
DTEND;VALUE=DATE:20280222
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 947941)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Study to Evaluate Safety and Efficacy of KarXT + KarX-E
 C as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-
 5)\nEstimated primary completion: 21 February 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06947941
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06189963-750@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Troculeucel: Phase 1/2 readout est. (NCT06189963)
DESCRIPTION:Troculeucel\, phase 1/2\, Alzheimer's Disease.\nStudy: Clinical
  Study of SNK01 in Participants With Moderate Alzheimer's Disease\nEstimat
 ed primary completion: March 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/troculeucel#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06189963
URL:https://assetmemo.bio/drug/troculeucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07228078-750@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Troculeucel: Phase 2 readout est. (NCT07228078)
DESCRIPTION:Troculeucel\, phase 2\, Alzheimer's Disease.\nStudy: Open-Label
  Extension Protocol to SNK01-AD01 Study\nEstimated primary completion: Apr
 il 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/troculeucel#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0722
 8078
URL:https://assetmemo.bio/drug/troculeucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01760005-665@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Leqembi (Lecanemab): Phase 2/3 readout est. (NCT01760005)
DESCRIPTION:Leqembi (Lecanemab)\, phase 2/3\, Alzheimer's Disease.\nStudy: 
 Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent De
 mentia. A Study of Potential Disease Modifying Treatments in Individuals a
 t Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a G
 enetic Mutation. Master Protocol DIAN-TU-001\nEstimated primary completion
 : April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lecanem
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 1760005
URL:https://assetmemo.bio/drug/lecanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01760005-686@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Etalanetug: Phase 2/3 readout est. (NCT01760005)
DESCRIPTION:Etalanetug\, phase 2/3\, Alzheimer's Disease.\nStudy: Dominantl
 y Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A
  Study of Potential Disease Modifying Treatments in Individuals at Risk fo
 r or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mu
 tation. Master Protocol DIAN-TU-001\nEstimated primary completion: April 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/etalanetug#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT01760005
URL:https://assetmemo.bio/drug/etalanetug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05269394-686@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Etalanetug: Phase 2/3 readout est. (NCT05269394)
DESCRIPTION:Etalanetug\, phase 2/3\, Alzheimer's Disease.\nStudy: Dominantl
 y Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A
  Study of Potential Disease Modifying Treatments in Individuals With a Typ
 e of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU
 )\nEstimated primary completion: April 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/etalanetug#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05269394
URL:https://assetmemo.bio/drug/etalanetug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07212062-665@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Leqembi (Lecanemab): Phase 2 readout est. (NCT07212062)
DESCRIPTION:Leqembi (Lecanemab)\, phase 2\, Alzheimer's Disease.\nStudy: Th
 e Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+
 X-EC in Participants With Alzheimer's Disease Who Are Currently Treated Wi
 th Lecanemab.\nEstimated primary completion: 1 April 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/lecanemab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07212062
URL:https://assetmemo.bio/drug/lecanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07612150-783@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:TML-6: Phase 2 readout est. (NCT07612150)
DESCRIPTION:TML-6\, phase 2\, Alzheimer's Disease.\nStudy: A Study to Evalu
 ate the Safety\, Tolerability\, and Efficacy of TML-6 in Participants With
  Early Alzheimer's Disease\nEstimated primary completion: 30 April 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/tml-6#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07612150
URL:https://assetmemo.bio/drug/tml-6#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05508789-664@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Kisunla (Donanemab): Phase 3 readout est. (NCT05508789)
DESCRIPTION:Kisunla (Donanemab)\, phase 3\, Alzheimer's Disease.\nStudy: A 
 Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzh
 eimer's Disease (TRAILBLAZER-ALZ 5)\nEstimated primary completion: May 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/donanemab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05508789
URL:https://assetmemo.bio/drug/donanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06885567-756@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:BEY2153: Phase 2 readout est. (NCT06885567)
DESCRIPTION:BEY2153\, phase 2\, Alzheimer's Disease.\nStudy: A Phase 2 Stud
 y to Evaluate the Safety and Efficacy of BEY2153 in Patients with Early Al
 zheimer's Disease\nEstimated primary completion: July 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/bey2153#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06885567
URL:https://assetmemo.bio/drug/bey2153#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07167966-684@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:AADvac1: Phase 2 readout est. (NCT07167966)
DESCRIPTION:AADvac1\, phase 2\, Alzheimer's Disease.\nStudy: Alzheimer's Ta
 u Platform: Regimen A - AADvac1\nEstimated primary completion: 31 August 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/aadvac1#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07167966
URL:https://assetmemo.bio/drug/aadvac1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06957418-684@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:AADvac1: Phase 2 readout est. (NCT06957418)
DESCRIPTION:AADvac1\, phase 2\, Alzheimer's Disease.\nStudy: Alzheimer's Ta
 u Platform: Master Protocol\nEstimated primary completion: 31 August 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/aadvac1#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06957418
URL:https://assetmemo.bio/drug/aadvac1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06976203-712@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280911
DTEND;VALUE=DATE:20280912
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 976203)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Study to Evaluate the Efficacy and Safety of KarXT + Ka
 rX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)\nEstimat
 ed primary completion: 11 September 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06976203
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06976216-712@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280911
DTEND;VALUE=DATE:20280912
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 976216)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Study to Evaluate the Efficacy and Safety of KarXT + Ka
 rX-EC for Cognitive Impairment in Alzheimer's Disease\nEstimated primary c
 ompletion: 11 September 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/xanomeline-trospium-chloride#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06976216
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07094516-700@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280914
DTEND;VALUE=DATE:20280915
SUMMARY:Lifonebart (VHB937): Phase 2 readout est. (NCT07094516)
DESCRIPTION:Lifonebart (VHB937)\, phase 2\, Alzheimer's Disease.\nStudy: A 
 Clinical Trial to Learn About the Effects of VHB937 in People With Early A
 lzheimer's Disease\nEstimated primary completion: 14 September 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/lifonebart-vhb937#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07094516
URL:https://assetmemo.bio/drug/lifonebart-vhb937#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06540833-708@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Deulumateperone: Phase 2 readout est. (NCT06540833)
DESCRIPTION:Deulumateperone\, phase 2\, Alzheimer's Disease.\nStudy: A Stud
 y to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psycho
 sis Associated With Alzheimer's Disease\nEstimated primary completion: 30 
 September 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/deulu
 mateperone#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06540833
URL:https://assetmemo.bio/drug/deulumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07252440-784@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281023
DTEND;VALUE=DATE:20281024
SUMMARY:Edaravone (TTYP01): Phase 2 readout est. (NCT07252440)
DESCRIPTION:Edaravone (TTYP01)\, phase 2\, Alzheimer's Disease.\nStudy: A S
 tudy to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Sympto
 matic Alzheimer's Disease\nEstimated primary completion: 23 October 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/edaravone-ttyp01#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07252440
URL:https://assetmemo.bio/drug/edaravone-ttyp01#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07011745-712@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281103
DTEND;VALUE=DATE:20281104
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT07
 011745)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Phase 3 Study to Evaluate the Safety and Efficacy of Ka
 rXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's D
 isease\nEstimated primary completion: 3 November 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07011745
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07011732-712@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281124
DTEND;VALUE=DATE:20281125
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT07
 011732)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Phase 3 Study to Evaluate the Safety and Efficacy of Ka
 rXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's D
 isease (ADAGIO-1)\nEstimated primary completion: 24 November 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/xanomeline-trospium-chloride
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070
 11732
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05564169-787@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Masitinib: Phase 3 readout est. (NCT05564169)
DESCRIPTION:Masitinib\, phase 3\, Alzheimer's Disease.\nStudy: Masitinib in
  Patients With Mild Alzheimer's Disease\nEstimated primary completion: Dec
 ember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/masitinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT055
 64169
URL:https://assetmemo.bio/drug/masitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04468659-665@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281221
DTEND;VALUE=DATE:20281222
SUMMARY:Leqembi (Lecanemab): Phase 3 readout est. (NCT04468659)
DESCRIPTION:Leqembi (Lecanemab)\, phase 3\, Alzheimer's Disease.\nStudy: AH
 EAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With 
 Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevate
 d Amyloid and Also in Participants With Early Preclinical Alzheimer's Dise
 ase and Intermediate Amyloid\nEstimated primary completion: 21 December 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/lecanemab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04468659
URL:https://assetmemo.bio/drug/lecanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06432166-751@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:2-hydroxybenzylamine acetate: Phase 1/2 readout est. (NCT06432166)
DESCRIPTION:2-hydroxybenzylamine acetate\, phase 1/2\, Alzheimer's Disease.
 \nStudy: 2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients
 \nEstimated primary completion: 30 December 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/2-hydroxybenzylamine-acetate#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06432166
URL:https://assetmemo.bio/drug/2-hydroxybenzylamine-acetate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284472-703@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Deramciclane: Phase 2/3 readout est. (NCT07284472)
DESCRIPTION:Deramciclane\, phase 2/3\, Alzheimer's Disease.\nStudy: Safety 
 and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzhe
 imer's Disease Dementia\nEstimated primary completion: January 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/deramciclane#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07284472
URL:https://assetmemo.bio/drug/deramciclane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284472-704@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Deraphan: Phase 2/3 readout est. (NCT07284472)
DESCRIPTION:Deraphan\, phase 2/3\, Alzheimer's Disease.\nStudy: Safety and 
 Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer
 's Disease Dementia\nEstimated primary completion: January 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/deraphan#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07284472
URL:https://assetmemo.bio/drug/deraphan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06847321-794@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:LHP588: Phase 2 readout est. (NCT06847321)
DESCRIPTION:LHP588\, phase 2\, Alzheimer's Disease.\nStudy: Study of LHP588
  in Subjects With P. Gingivalis-Positive Alzheimer's Disease\nEstimated pr
 imary completion: 31 January 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/lhp588#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06847321
URL:https://assetmemo.bio/drug/lhp588#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07205601-748@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:RB-ADSC: Phase 2 readout est. (NCT07205601)
DESCRIPTION:RB-ADSC\, phase 2\, Alzheimer's Disease.\nStudy: Study of Intra
 cerebroventricular Injections of Autologous Adipose-Derived Stem Cells (RB
 -ADSCs) in Participants With Mild-Moderate Alzheimer's Disease\nEstimated 
 primary completion: February 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/rb-adsc#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07205601
URL:https://assetmemo.bio/drug/rb-adsc#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07191028-760@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:NeuroAiD II (MLC901): Phase 3 readout est. (NCT07191028)
DESCRIPTION:NeuroAiD II (MLC901)\, phase 3\, Alzheimer's Disease.\nStudy: A
 lzheimer's Disease THErapy With NEuroaid II\nEstimated primary completion:
  February 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mlc90
 1#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 191028
URL:https://assetmemo.bio/drug/mlc901#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07459660-707@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Betovumeline/fesoterodine (ML-007C-MA): Phase 2 readout est. (NCT07
 459660)
DESCRIPTION:Betovumeline/fesoterodine (ML-007C-MA)\, phase 2\, Alzheimer's 
 Disease.\nStudy: An Open-Label Study of ML-007C-MA in Adults With Alzheime
 r's Disease Psychosis\nEstimated primary completion: March 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/betovumeline-fesoterodine-ml-0
 07c-ma#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07459660
URL:https://assetmemo.bio/drug/betovumeline-fesoterodine-ml-007c-ma#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05462106-680@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:ACI-24.060: Phase 1/2 readout est. (NCT05462106)
DESCRIPTION:ACI-24.060\, phase 1/2\, Alzheimer's Disease.\nStudy: A Study t
 o Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Synd
 rome (ABATE Study)\nEstimated primary completion: April 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/aci-24-060#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05462106
URL:https://assetmemo.bio/drug/aci-24-060#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06653153-669@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Remternetug: Phase 3 readout est. (NCT06653153)
DESCRIPTION:Remternetug\, phase 3\, Alzheimer's Disease.\nStudy: A Study of
  Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)\
 nEstimated primary completion: April 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/remternetug#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06653153
URL:https://assetmemo.bio/drug/remternetug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06194799-702@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Remlifanserin: Phase 3 readout est. (NCT06194799)
DESCRIPTION:Remlifanserin\, phase 3\, Alzheimer's Disease.\nStudy: ACP-204 
 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study\nE
 stimated primary completion: April 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/remlifanserin#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06194799
URL:https://assetmemo.bio/drug/remlifanserin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07033494-799@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:MK-2214: Phase 2 readout est. (NCT07033494)
DESCRIPTION:MK-2214\, phase 2\, Alzheimer's Disease.\nStudy: A Clinical Stu
 dy of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)\nEsti
 mated primary completion: 30 April 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/mk-2214#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07033494
URL:https://assetmemo.bio/drug/mk-2214#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06937229-712@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290622
DTEND;VALUE=DATE:20290623
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 937229)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Study to Evaluate the Long-term Efficacy and Safety of 
 KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)\nEstimated
  primary completion: 22 June 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/xanomeline-trospium-chloride#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06937229
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07688213-779@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:SAR448851: Phase 2 readout est. (NCT07688213)
DESCRIPTION:SAR448851\, phase 2\, Alzheimer's Disease.\nStudy: A Study to I
 nvestigate the Safety and Effectiveness of SAR448851 in Participants With 
 Early Alzheimer's Disease\nEstimated primary completion: 31 July 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/sar448851#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07688213
URL:https://assetmemo.bio/drug/sar448851#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07602582-664@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Kisunla (Donanemab): Phase 3 readout est. (NCT07602582)
DESCRIPTION:Kisunla (Donanemab)\, phase 3\, Alzheimer's Disease.\nStudy: A 
 Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (T
 RAILBLAZER-ALZ 3-EXT).\nEstimated primary completion: September 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/donanemab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07602582
URL:https://assetmemo.bio/drug/donanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07827768-678@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291015
DTEND;VALUE=DATE:20291016
SUMMARY:AV-1959R: Phase 2 readout est. (NCT07827768)
DESCRIPTION:AV-1959R\, phase 2\, Alzheimer's Disease.\nStudy: AV-1959R Vacc
 ine in Individuals With Preclinical Alzheimer's Disease\nEstimated primary
  completion: 15 October 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/av-1959r#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07827768
URL:https://assetmemo.bio/drug/av-1959r#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05809908-718@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Tricaprilin: Phase 3 readout est. (NCT05809908)
DESCRIPTION:Tricaprilin\, phase 3\, Alzheimer's Disease.\nStudy: Tricaprili
 n Phase 3 ALTER-AD (Alternative-Alzheimer Disease) Study\nEstimated primar
 y completion: January 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/tricaprilin#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05809908
URL:https://assetmemo.bio/drug/tricaprilin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06274528-735@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Dayvigo (Lemborexant): Phase 2 readout est. (NCT06274528)
DESCRIPTION:Dayvigo (Lemborexant)\, phase 2\, Alzheimer's Disease.\nStudy: 
 DORA and LP in Alzheimer's Disease Biomarkers\nEstimated primary completio
 n: 31 March 2030. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lem
 borexant#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06274528
URL:https://assetmemo.bio/drug/lemborexant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07571161-664@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Kisunla (Donanemab): Phase 3 readout est. (NCT07571161)
DESCRIPTION:Kisunla (Donanemab)\, phase 3\, Alzheimer's Disease.\nStudy: Do
 nanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpai
 red (Preclinical) Alzheimer's Disease\nEstimated primary completion: April
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/donanemab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07571161
URL:https://assetmemo.bio/drug/donanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07636811-697@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300518
DTEND;VALUE=DATE:20300519
SUMMARY:Mivelsiran: Phase 2 readout est. (NCT07636811)
DESCRIPTION:Mivelsiran\, phase 2\, Alzheimer's Disease.\nStudy: A Study to 
 Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-A
 ssociated Alzheimer's Disease (DS-AD)\nEstimated primary completion: 18 Ma
 y 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/mivelsiran#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076368
 11
URL:https://assetmemo.bio/drug/mivelsiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06384573-665@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Leqembi (Lecanemab): Phase 3 readout est. (NCT06384573)
DESCRIPTION:Leqembi (Lecanemab)\, phase 3\, Alzheimer's Disease.\nStudy: DI
 AN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Dise
 ase\nEstimated primary completion: June 2030. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/lecanemab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06384573
URL:https://assetmemo.bio/drug/lecanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06996730-664@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Kisunla (Donanemab): Phase 2/3 readout est. (NCT06996730)
DESCRIPTION:Kisunla (Donanemab)\, phase 2/3\, Alzheimer's Disease.\nStudy: 
 A Study of Donanemab\, RG6289\, or the Combination of Donanemab and RG6289
  in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Auto
 somal-Dominant Alzheimer's Disease\nEstimated primary completion: 1 June 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/donanemab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06996730
URL:https://assetmemo.bio/drug/donanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06996730-11329@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Nivegacetor: Phase 2/3 readout est. (NCT06996730)
DESCRIPTION:Nivegacetor\, phase 2/3\, Alzheimer's Disease.\nStudy: A Study 
 of Donanemab\, RG6289\, or the Combination of Donanemab and RG6289 in Pres
 enilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Do
 minant Alzheimer's Disease\nEstimated primary completion: 1 June 2030. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/nivegacetor#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06996730
URL:https://assetmemo.bio/drug/nivegacetor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07599670-671@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:ABBV-1758: Phase 1/2 readout est. (NCT07599670)
DESCRIPTION:ABBV-1758\, phase 1/2\, Alzheimer's Disease.\nStudy: A Study to
  Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intr
 avenous Injections in Participants With Alzheimer's Disease\nEstimated pri
 mary completion: October 2030. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/abbv-1758#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07599670
URL:https://assetmemo.bio/drug/abbv-1758#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06964230-724@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:T3D-959: Phase 2/3 readout est. (NCT06964230)
DESCRIPTION:T3D-959\, phase 2/3\, Alzheimer's Disease.\nStudy: A Phase 2b/3
  Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease
  Subjects\nEstimated primary completion: April 2031. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/t3d-959#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06964230
URL:https://assetmemo.bio/drug/t3d-959#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07717411-670@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20320730
DTEND;VALUE=DATE:20320731
SUMMARY:Trontinemab: Phase 3 readout est. (NCT07717411)
DESCRIPTION:Trontinemab\, phase 3\, Alzheimer's Disease.\nStudy: A Study of
  Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression
  to Symptomatic Alzheimer's Disease\nEstimated primary completion: 30 July
  2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/trontinemab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077174
 11
URL:https://assetmemo.bio/drug/trontinemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06647498-669@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20340331
DTEND;VALUE=DATE:20340401
SUMMARY:Remternetug: Phase 2/3 readout est. (NCT06647498)
DESCRIPTION:Remternetug\, phase 2/3\, Alzheimer's Disease.\nStudy: A Study 
 of a Potential Disease Modifying Treatment in Individuals at Risk for or W
 ith a Type of Early Onset AD Caused by a Genetic Mutation\nEstimated prima
 ry completion: March 2034. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/remternetug#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06647498
URL:https://assetmemo.bio/drug/remternetug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05552157-669@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20340330
DTEND;VALUE=DATE:20340331
SUMMARY:Remternetug: Phase 2/3 readout est. (NCT05552157)
DESCRIPTION:Remternetug\, phase 2/3\, Alzheimer's Disease.\nStudy: A Study 
 of Potential Disease Modifying Treatments in Individuals at Risk for or Wi
 th a Type of Early Onset AD Caused by a Genetic Mutation\nEstimated primar
 y completion: 30 March 2034. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/remternetug#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05552157
URL:https://assetmemo.bio/drug/remternetug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
